Cardiome Pharma (CRME) to Cut Employee Headcount by 85%
Tweet
Share
E-mailGet Alerts CRME Hot Sheet
Join SI Premium – FREE
Cardiome Pharma (Nasdaq: CRME) today announced that the Company is undertaking a significant workforce reduction as a response to the recently announced termination of Merck's development efforts relating to the vernakalant oral program.
The workforce reduction eliminates all positions focused on internal research activities along with certain supporting functions. The reduction in personnel will decrease the total number of employees by approximately 85%. The company expects to incur up to $5.0 million in severance and other charges related to this restructuring over the remainder of the year.
The workforce reduction eliminates all positions focused on internal research activities along with certain supporting functions. The reduction in personnel will decrease the total number of employees by approximately 85%. The company expects to incur up to $5.0 million in severance and other charges related to this restructuring over the remainder of the year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
- Serve Robotics (SERV) Enters Production Agreement with Magna (MGA) to Scale Robot Manufacturing
- Bogota Financial (BSBK) Announces 237K Share Buyback
Create E-mail Alert Related Categories
Corporate News, Trading HaltsRelated Entities
LayoffsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
